Latest advances in the development of tuberculosis vaccines in global clinical trials: a review
10.16250/j.32.1374.2023102
- VernacularTitle:国内外结核病临床在研疫苗最新研究进展
- Author:
Fangbin ZHOU
1
,
2
;
Yilong ZHANG
1
,
2
;
Dongmei ZHANG
1
Author Information
1. Department of Tropical Diseases, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China
2. Co-first authors
- Publication Type:Journal Article
- Keywords:
Tuberculosis;
Mycobacterium tuberculosis;
Vaccine;
Clinical trial
- From:
Chinese Journal of Schistosomiasis Control
2024;36(2):201-206
- CountryChina
- Language:Chinese
-
Abstract:
Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.
